Am Klopferspitz 19
82152 Martinsried, de
+49 (89) 12017222
Matured vector technologies open industrial gene therapy and vaccine markets to German Biotech
Viral vectors gain traction in the industry(PresseBox) ( München, )
Gene replacement therapy, genetic vaccination and cancer immunotherapies are becoming a major focus of medical research, and genetic modification of patient cells is their key element of success. In most programs, the question of WHICH genes need to be modified has been answered. This makes the question of HOW to introduce and control a gene in the patient the biggest obstacle on the way to a cure. Every pathology, every tissue or cell type holds new sets of challenges and necessitates the development of a customized gene delivery system.
Vectors derived from viruses are considered the most promising gene delivery tools today. Viruses have evolved naturally over millions of years to become ideal gene transfer vehicles. By replacing key elements of the virus genome with therapeutically helpful genes, virus specialists such as SIRION Biotech can build and refine highly complex vectors, destined to become the next big pharmaceutical achievement since engineered antibodies.
Their successful signing of 3 major collaboration deals with industrial drug and therapy development companies in 2015 has demonstrated that the demand for gene delivery experts is on the rise. Together, these strategic alliances join in the development of unprecedented gene therapies that will answer medicine’s most pressing questions: The fight against cancer, genetically linked disabilities and the threat of epidemic diseases in an ever-growing populous.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an firstname.lastname@example.org.